Next Article in Journal
The Expression of MTUS1/ATIP and Its Major Isoforms, ATIP1 and ATIP3, in Human Prostate Cancer
Next Article in Special Issue
Helical Tomotherapy in Children and Adolescents: Dosimetric Comparisons, Opportunities and Issues
Previous Article in Journal
Biomarkers in Prostate Cancer Epidemiology
Previous Article in Special Issue
Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy
Open AccessReview

Combined Hyperthermia and Radiotherapy for the Treatment of Cancer

Department of Pathology, Scott & White Hospital and the Texas A&M Health Science Center, College of Medicine, Temple, TX 76504, USA
Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center and Harvard Medical School, Boston, MA 02115, USA
Department of Radiation Oncology, The University of Texas MD Anderson Medical Center, Houston, TX 77030, USA
Author to whom correspondence should be addressed.
Cancers 2011, 3(4), 3799-3823;
Received: 15 July 2011 / Revised: 23 September 2011 / Accepted: 23 September 2011 / Published: 30 September 2011
(This article belongs to the Special Issue Radiation and Cancers)
Radiotherapy is used to treat approximately 50% of all cancer patients, with varying success. Radiation therapy has become an in­tegral part of modern treatment strategies for many types of cancer in recent decades, but is associated with a risk of long-term adverse effects. Of these side effects, car­diac complications are particularly relevant since they not only adversely affect quality of life but can also be potentially life-threat­ening. The dose of ionizing radiation that can be given to the tumor is determined by the sensitivity of the surrounding normal tissues. Strategies to improve radiotherapy therefore aim to increase the effect on the tumor or to decrease the effects on normal tissues, which must be achieved without sensitizing the normal tissues in the first approach and without protecting the tumor in the second approach. Hyperthermia is a potent sensitizer of cell killing by ionizing radiation (IR), which can be attributed to the fact that heat is a pleiotropic damaging agent, affecting multiple cell components to varying degrees by altering protein structures, thus influencing the DNA damage response. Hyperthermia induces heat shock protein 70 (Hsp70; HSPA1A) synthesis and enhances telomerase activity. HSPA1A expression is associated with radioresistance. Inactivation of HSPA1A and telomerase increases residual DNA DSBs post IR exposure, which correlates with increased cell killing, supporting the role of HSPA1A and telomerase in IR-induced DNA damage repair. Thus, hyperthermia influences several molecular parameters involved in sensitizing tumor cells to radiation and can enhance the potential of targeted radiotherapy. Therapy-inducible vectors are useful for conditional expression of therapeutic genes in gene therapy, which is based on the control of gene expression by conventional treatment modalities. The understanding of the molecular response of cells and tissues to ionizing radiation has lead to a new appreciation of the exploitable genetic alterations in tumors and the development of treatments combining pharmacological interventions with ionizing radiation that more specifically target either tumor or normal tissue, leading to improvements in efficacy. View Full-Text
Keywords: heat shock proteins; radiotherapy; hyperthermia; cancer; hypoxia heat shock proteins; radiotherapy; hyperthermia; cancer; hypoxia
MDPI and ACS Style

Kaur, P.; Hurwitz, M.D.; Krishnan, S.; Asea, A. Combined Hyperthermia and Radiotherapy for the Treatment of Cancer. Cancers 2011, 3, 3799-3823.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop